



CITICHEMTM INDIA LIMITED

512, Yogeshwar Premises, 5th Floor, 135 Kazi Sayed Street, Masjid Bunder (W), Mumbai - 400 003
Email.: marketing@citichemindia.com Website : www.citichemindia.com Tel.: 022 - 49732489
CIN : U24100MH1992PLC065975 ISIN : INEOA8401016 GST No. 27AACCC9682M1ZZ
fsa Central Lic. No. 11519018000620 State Lic. No 10020022010907 Pharma Lic. No. MH - TZS - 335245

To,
The Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai 400 001.

Date: 14th November, 2025

Scrip Name: CITICHEM INDIA LIMITED
Company Scrip No.: 544324

Sub: Outcome of the Board Meeting held on 14th November, 2025.

Dear Sirs,

This is in reference to our earlier intimation dated 10th November, 2025, pursuant to Regulation 29 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations"), regarding holding of Board Meeting on 14th November, 2025.

In this regard, please note that the Board of Directors at its meeting held today i.e. 14th November, 2025, has, inter alia:

1. Approved the Unaudited Financial Results of the Company for the half year ended 30th September, 2025. Accordingly, we are enclosing herewith Unaudited Standalone Financial Results along with Limited Review Report thereon.
2. Approved raising of funds through issuance of up to 4700000 warrants convertible into 4700000 Equity Shares of Face Value of Rs. 10/- each at a price of Rs. 29/- per warrant aggregating to INR 136,300,000 to the promoters and others (i.e. persons/entities not forming part of the promoter and promoter group), on a preferential basis in accordance with Chapter V of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations"), subject to the approval of regulatory/ statutory authorities and the shareholders of the Company at the ensuing Extra-ordinary General Meeting and such other permissions, sanctions and statutory approvals, as may be required and in supersession of the earlier approved preferential issue of convertible warrants at the Annual General Meeting held on 30th September, 2025.

The Relevant Date in terms of SEBI ICDR Regulations is Friday, 14th November, 2025.

Each warrant is convertible into one (1) equity share and the conversion can be exercised at any time during the period of 18 months from the date of allotment of warrants on such other terms and conditions as applicable.



CITICHEMTM INDIA LIMITED

512, Yogeshwar Premises, 5th Floor, 135 Kazi Sayed Street, Masjid Bunder (W), Mumbai - 400 003
Email.: marketing@citichemindia.com Website : www.citichemindia.com Tel.: 022 - 49732489
CIN : U24100MH1992PLC065975 ISIN : INEOA8401016 GST No. 27AACCC9682M1ZZ
fssai Central Lic. No. 11519018000620 State Lic. No 10020022010907 Pharma Lic. No. MH - T2S - 335245

A detailed disclosure in adherence to Listing Regulations read with SEBI Circulars No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11 November, 2024 and No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31 December, 2024 is disclosed in Annexure – A.

The meeting of the Board of Directors of the Company commenced at 7.30 pm and concluded at 9.00 pm.

Kindly take the same on record.

Yours Faithfully,
For Citichem India Limited


Arif Esmail Merchant
Managing Director
Din: 00500363





CITICHEMTM INDIA LIMITED

512, Yogeshwar Premises, 5th Floor, 135 Kazi Sayed Street, Masjid Bunder (W), Mumbai - 400 003
 Email.: marketing@citichemindia.com Website : www.citichemindia.com Tel.: 022 - 49732489
 CIN : U24100MH1992PLC065975 ISIN : INEOA8401016 GST No. 27AACCC9682M1ZZ
fsa Central Lic. No. 11519018000620 State Lic. No 10020022010907 Pharma Lic. No. MH - TZS - 335245

Annexure A

Disclosure in terms of Regulation 30 of the Listing Regulations read with SEBI Circulars

Preferential Issue

Sl. No.	Particulars	Details
1.	Type of securities proposed to be issued (viz. equity shares, convertibles, etc.)	Convertible Warrants
2.	Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)	Preferential Allotment
3.	Total number of securities proposed to be issued or the total amount for which the securities will be issued (approximately)	Total number of securities proposed to be issued - 4700000 warrants convertible into 4700000 equity shares of the face value of INR 10/- each.
4.	Additional Information in case of Preferential Issue:	
i	Name of the Investors and Number of Shares via Warrants to be issued:	Subject to approval of shareholders of the Company, the warrants are proposed to be issued to: 1. Arif Esmail Merchant: 2150000 Warrants 2. Hashim Arif Merchant: 2150000 Warrants 3. Padmakar Jagannath Murodiya: 400000 Warrants
ii	Post allotment of securities - outcome of the subscription	Shall be intimated at the time of allotment. (The Warrants proposed to be issued at price in terms of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018).
	issue price / allotted price (in case of convertibles),	INR 29/- per warrant
	number of investors;	3
iii	in case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument;	Shall be intimated at the time of conversion / lapse.

**Independent Auditor's Review Report on Review of Interim Financial Results
To The Board of Directors of
Citichem India Limited**

We have reviewed the accompanying statement of Unaudited Financial Results of **Citichem India Limited** ('The Company') for the half year ended 30th September 2025 ('the statement'), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors / Committee of Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel & analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the applicable Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Mumbai
Date: September 14, 2025



For: NGST & Associates
Chartered Accountants
Firm Reg. No. - 135159W

Bhupendra

Bhupendra Gandhi
Partner

Membership No. 122296
UDIN -25122296BMIAGJ5377

Citichem India Limited
Unaudited result for the half year ended on 30th September 2025

Rs. In Lacs

Particulars	For half year ended 30.09.2025	For half year ended 30.09.2024	For the year ended 31.03.2025	For the year ended 31.03.2024
Income				
Revenue from operations	851.68	167.26	1,869.54	1,960.58
Other operating income	158.32	-	3,567.89	-
Other income	66.81	-	36.05	-
Total Revenue	1,076.81	167.26	5,473.47	1,960.58
Expenses:				
Purchase of stock - in - trade	1,085.72	128.84	1,817.59	881.81
Changes in inventories of finished goods	(248.71)	(21.21)	3,129.96	728.57
Employee benefits expense	12.78	30.71	29.11	81.40
Other Expenses	106.28	11.86	299.22	89.51
Total Expenses	956.06	150.21	5,275.87	1,781.29
Profit before Interest, Tax, Depreciation and amortization	120.75	17.06	197.60	179.29
Depreciation and amortisation Expenses	2.88	0.91	0.70	1.63
Finance Cost	26.47	0.09	30.61	6.64
Profit/(Loss) before Tax	91.40	16.05	166.29	171.02
Tax expense				
Current tax expense for current year	23.40	3.80	44.00	32.00
Deferred Tax	-	-	(0.59)	0.25
Total Tax Expenses	23.40	3.80	43.41	32.25
Profit / (Loss) for the year	68.00	12.25	122.87	138.78
Earnings per equity share				
(1) Basic	1.36	0.25	2.26	2.78
(2) Diluted	1.36	0.25	2.26	2.78

Notes:

- 1 The above unaudited Financial Results were reviewed by the Audit Committee and thereafter were approved by the Board of Directors of the Company at its meeting held on 18 March 2025. The statutory auditors have carried out the limited review of the above results.
- 2 The segment-wise reporting as defined in AS-7 is not applicable since the Company has only one reportable segment "Chemicals"
- 3 As per MCA Notification dated 16th February 2015, the companies whose shares are listed on BSE SME platform as referred to in chapter XB of SEBI (Issue of Capital and Disclosure requirements) regulations, 2009 are exempted from the Compulsory requirement of adoption of IND-AS. As the company is covered under exempted from the Compulsory requirement of adoption of IND AS. Hence it has not adopted IND AS for preparation of Financial Statements
- 4 Corresponding figures of the previous period have been re-grouped / re-arranged wherever necessary to make them comparable.

 

Citichem India Limited
Statement of assets and liabilities as at 30 September 2025

Rs. In Lacs		
Particulars	For half year ended 30.09.2025	For the year ended 31.03.2025
EQUITY AND LIABILITIES		
Shareholder's Funds		
Share Capital	680.00	680.00
Reserves and Surplus	1,397.91	1,329.91
Non-Current Liabilities		
Long-term borrowings	4.93	61.78
Current Liabilities		
Short-term borrowings	699.90	476.72
Trade payables		
- Micro, Small & Medium Enterprises	80.41	80.41
- Other than Micro, Small & Medium Enterprises	2,785.51	4,195.37
Other current liabilities	4.05	67.67
Short-term provisions	123.95	100.55
	5,776.67	6,992.41
Assets		
Non-current assets		
Fixed assets		
Tangible assets	95.62	6.46
Non-current investments		-
Deferred tax assets (net)	0.75	0.75
Long term loans and advances	33.35	2.35
Other Non current assets	780.66	749.00
Current assets		
Inventories	867.43	618.72
Trade receivables	3,845.28	5,108.33
Cash and cash equivalents	41.54	445.72
Short Term Loans & Advances	4.89	10.00
Other current assets	107.16	51.08
TOTAL	5,776.67	6,992.41



Citichem India Limited

Cash Flow Statement as at 30 September 2025

Particulars	For half year ended 30.09.2025	Rs. In Lacs For the year ended 31.03.2025
(A) Cash Flow from Operating Activities		
Restated Net Profit Before Tax and Extraordinary Items	91.40	166.29
<u>Adjustments For:</u>		
Interest and Finance Charges Paid	26.47	30.61
Depreciation	2.88	0.70
Interest Received	(27.79)	-
Operating profit before working capital changes	92.97	197.60
<u>Changes in Working Capital</u>		
(Increase)/Decrease in Trade Receivables and loans & advances	1,149.43	(2,805.17)
(Increase)/Decrease in Inventories	(248.71)	3,129.96
Increase/(Decrease) in Long Term Provisions	-	-
Increase/(Decrease) in Trade Payables and other liabilities	(1,473.47)	(1,672.53)
Increase/(Decrease) in Short Term Provisions	-	-
Cash Generated from / (used in) operating activities	(479.79)	(1,150.14)
Less : Income Tax paid	-	(1.20)
Cash Flow before extraordinary items	(479.79)	(1,151.34)
Extraordinary items	-	-
Net cash generated from / (used in) Operating Activities.....A	(479.79)	(1,151.34)
(B) Cash Flow from Investing Activities		
(Increase)/Decrease in Non-Current Investment	-	-
Interest Received	27.79	-
(Purchase) of Tangible Fixed Assets	(92.04)	(0.27)
Sale of Tangible Fixed Assets	-	2.89
Net cash generated from / (used in) Investing Activities.....B	(64.25)	2.62
(C) Cash Flow from financing Activities		
Proceeds from issue of Share Capital	-	1,135.00
Increase/(Decrease) in Short Term Borrowings	223.18	476.72
Increase/(Decrease) in Long Term Borrowings	(56.85)	(46.42)
Interest and Finance Charges Paid	(26.47)	(30.61)
Net cash generated from / (used in) Financing Activities.....C	139.86	1,534.69
Net increase in cash and cash equivalents (A+B+C)	(404.19)	385.97
Cash and cash equivalents at the beginning	445.72	59.76
Cash and cash equivalents at the end	41.54	445.72

